Proteome instability is an immunogenic therapeutic vulnerability in mismatch repair deficient cancer
It is produced by modifying the Cterminus of the MTII scaffold replacing the terminal amide with a hydroxyl group yielding a related cyclic peptide with a distinct receptorselectivity profile while retaining the lactambridged, enzymatically stable architecture of its parent compound
Study-related adverse events Adverse reactions reported in 5% of patients and occurring more frequently with Victoza compared with placebo included nausea (21.4% vs 4.4%), vomiting (12.1% vs 2.2%), diarrhea (7.1% vs 2.9%), constipation (5.7% vs 1.5%), increased lipase (15.0% vs 8.8%), GFR decreased (6.4% vs 5.1%), and headache (5.0% vs 2.9%)
In SURMOUNT-3, 600 participants are randomized to receive either tirzepatide at the maximally tolerated dose or placebo following a structured intensive 12-week lifestyle intervention
Finding Support: How IV Therapy May Assist with Lyme Disease Symptoms The Daily Battle: Living with Chronic Lyme Symptoms If you're on a journey with Lyme disease, you know it's more than just a diagnosisit's a daily battle
Nutrients 10(4):522